risperidone has been researched along with Arteriosclerosis, Coronary in 4 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examined the clinical significance of switching from olanzapine, quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular disease (CVD) according to the Framingham Risk Score (FRS) and metabolic syndrome status." | 9.17 | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. ( Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS, 2013) |
| "This study examined the clinical significance of switching from olanzapine, quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular disease (CVD) according to the Framingham Risk Score (FRS) and metabolic syndrome status." | 5.17 | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. ( Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS, 2013) |
| "Clozapine is a superior agent for treatment-refractory patients with schizophrenia, but is underutilized in the US, likely due to the risk of side effects." | 3.75 | Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. ( Feldman, S; Fowler, DR; Kelly, DL; Linthicum, J; Love, RC; McMahon, RP; Shim, JC; Wagner, T; Wehring, HJ, 2009) |
| "Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2." | 1.32 | Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stroup, TS | 1 |
| Byerly, MJ | 1 |
| Nasrallah, HA | 1 |
| Ray, N | 1 |
| Khan, AY | 1 |
| Lamberti, JS | 1 |
| Glick, ID | 1 |
| Steinbook, RM | 1 |
| McEvoy, JP | 1 |
| Hamer, RM | 1 |
| Kelly, DL | 1 |
| Wehring, HJ | 1 |
| Linthicum, J | 1 |
| Feldman, S | 1 |
| McMahon, RP | 1 |
| Love, RC | 1 |
| Wagner, T | 1 |
| Shim, JC | 1 |
| Fowler, DR | 1 |
| Alméras, N | 1 |
| Després, JP | 1 |
| Villeneuve, J | 1 |
| Demers, MF | 1 |
| Roy, MA | 1 |
| Cadrin, C | 1 |
| Mottard, JP | 1 |
| Bouchard, RH | 1 |
| Karagianis, JL | 1 |
| Dunayevich, E | 1 |
1 trial available for risperidone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepi | 2013 |
3 other studies available for risperidone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Cause of Death; Clozapine; Coron | 2009 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary | 2004 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Biomarkers; Coronary Artery Disease; Cross-Sectional St | 2005 |